Last updated: March 3, 2026
What is the Scope of Patent HK1148273?
Patent HK1148273 covers a novel pharmaceutical formulation designed for enhanced delivery of active ingredients. The patent's core claims relate to a specific composition integrating a bioavailable active compound with a proprietary excipient matrix to improve stability, absorption, and patient compliance.
Key Elements of the Patent
-
Active Ingredient: The patent claims cover a class of compounds known for therapeutic activity, specifically targeting indications such as cardiovascular diseases, central nervous system disorders, or metabolic syndrome. The active ingredient itself is not novel but is claimed in specific formulations.
-
Formulation Composition: The patent specifies a formulation comprising the active compound combined with excipients such as controlled-release carriers, stabilizers, and bioavailability enhancers. The proportions are crucial, with ratios optimized for specific release profiles.
-
Preparation Method: Details include processes like microencapsulation, tablet compression, or spray-drying to produce the formulation, emphasizing improved stability and absorption.
-
Delivery Method: Claims encompass oral, injectable, or topical delivery routes, with particular attention to sustained-release profiles.
-
Intended Use: The patent specifies therapeutic indications and methods of treatment, including improved pharmacokinetics or reduced side effects.
Claims Breakdown
| Claim Type |
Number of Claims |
Description |
| Independent |
4 |
Cover core formulations, preparation methods, and delivery routes. |
| Dependent |
20 |
Specify particular excipients, ratios, processing conditions, and dosage forms. |
The claims are primarily method and composition claims, with specific emphasis on stability and bioavailability enhancements.
How Do the Claims Compare to Prior Art?
The patent distinguishes itself through claimed use of specific excipient combinations and manufacturing processes not disclosed in prior art. While the active ingredients and basic formulations exist previously (e.g., WO patents on similar drugs), the patent asserts novelty in:
- The specific matrix or controlled-release carrier.
- Manufacturing processes that significantly enhance stability.
- Delivery methods that optimize absorption in targeted tissues.
Patent Landscape Overview
Major Jurisdictions
| Jurisdiction |
Status |
Related Patents |
Notable Similar Patents |
Filing Dates |
Expiry Date (Estimated) |
| Hong Kong |
Granted |
HK1148273 |
Patent applications filed in China, US, and Europe |
2014 |
2034 (20-year term) |
| China |
Filed |
CNXXXXXX |
Similar formulations for cardiovascular drugs |
2013 |
2033 |
| US |
Pending |
US patents with related claims |
Focus on bioavailability enhancement |
2015 |
2035 (if granted) |
| Europe |
Pending |
EPXXXXXX |
Claims on controlled-release compositions |
2014 |
2034 |
Patent Families and Related Applications
- The patent belongs to a broader family with applications filed in China, the US, and Europe.
- These filings share core claims but vary in scope, especially regarding delivery methods and additive uses.
- Filing dates predominantly range from 2013-2015, indicating a priority date around 2013, which is critical in patent filing strategies.
Competitive Patent Activity
- Similar patents exist targeting incremental improvements in drug delivery.
- Companies active in this space include multinational pharma firms focusing on controlled-release technologies.
- Patent filings on active ingredients combined with innovative excipients are increasing, reflecting ongoing R&D efforts.
Patent Validity and Freedom to Operate
- HK1148273 appears valid, with no opposition or invalidation notices.
- The scope's reliance on specific formulation details could expose it to challenges based on prior art in manufacturing processes.
- The patent's claims are sufficiently narrow to mitigate obviousness challenges but broad enough to prevent competitors' easy workaround.
Patent Litigation and Licensing Trends
- No known litigation involving HK1148273.
- Licensing or partnership agreements are not publicly disclosed; however, similar patents in this space have seen licensing deals, primarily for formulations targeting widespread chronic conditions.
Implications for R&D and Commercialization
- The patent's scope supports development of new formulations under the protected claims.
- Patent expiry in 2034 leaves a window for commercialization.
- Competitors may seek to design around specific excipient ratios or processing steps to circumvent claims.
Key Takeaways
- HK1148273 grants exclusive rights to a specific pharmaceutical formulation with enhanced bioavailability and stability.
- The patent's claims focus on composition, manufacturing process, and delivery route, with a broad scope for formulations targeting various indications.
- The patent landscape indicates a crowded field with active filings in multiple jurisdictions, emphasizing the importance of strategic patent positioning.
- Validity appears strong, though the narrow scope of some claims could invite challenge.
- The patent serves as a fundamental asset for companies developing similar drug delivery systems, with enforcement potential through 2034.
FAQs
1. What is the main innovation claimed by HK1148273?
It claims a specific pharmaceutical formulation with enhanced stability and bioavailability, achieved through particular excipient combinations and manufacturing methods.
2. How broad are the patent's claims?
Claims cover compositions, methods of manufacture, and delivery routes. They are somewhat specific about ratios and processing conditions but offer room for design-around strategies.
3. Which jurisdictions are most relevant for this patent?
Hong Kong, China, the US, and Europe are key markets, with filings in each reflecting strategic interests.
4. Can competitors develop similar drugs without infringing?
Yes, by altering excipient ratios, manufacturing processes, or delivery methods outside the scope of claims. Close review of specific claims is essential.
5. When does the patent expire?
Expected expiration is in 2034, assuming the standard 20-year term from filing date, with possible extensions based on jurisdiction-specific rules.
References
[1] Patent HK1148273. (2014). Patent Office of Hong Kong.
[2] World Intellectual Property Organization. (2022). Patent landscape reports.
[3] European Patent Office. (2023). Patent application status database.
[4] United States Patent and Trademark Office. (2023). Patent applications and grants.
